SCHEMBL4886359

SCHEMBL4886359

FC(F)(F)c1ccnn1-c1ncccn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.40
L3MBTL1 Q9Y468 2/20 0.37
OXTR P30559 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
AVPR1A P37288 1/20 0.34
NTRK1 P04629 1/20 0.33
TGFBR1 P36897 1/20 0.31
HPGD P15428 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
GAA P10253 1/20 0.31
POLB P06746 2/20 0.31
SLC6A7 Q99884 1/20 0.31
MAT2A P31153 1/20 0.31
EPHX2 P34913 1/20 0.30
ADRB1 P08588 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882320 0.79 OXTR (0.49) KDM4EOXTRAVPR1ASMN1; SMN2GAA
SCHEMBL30942665 0.78 KDM4E (0.43) KDM4EL3MBTL1ALDH1A1MEN1MAPT
SCHEMBL30987262 0.75 KDM4E (0.41) KDM4EL3MBTL1ALDH1A1MEN1MAPT
SCHEMBL16321386 0.75 KDM4E (0.41) KDM4EL3MBTL1ALDH1A1MEN1MAPT
SCHEMBL12273672 0.71 KDM4E (0.42) KDM4EL3MBTL1ALDH1A1MEN1MAPT
SCHEMBL30254265 0.71 CYP11B2 (0.44) KDM4EL3MBTL1NTRK1EPHX2HTT
SCHEMBL28685308 0.71 KDM4E (0.42) KDM4EL3MBTL1ALDH1A1MAPTKMT2A
SCHEMBL2051700 0.71 KDM4E (0.45) KDM4EALDH1A1MEN1MAPTKMT2A
SCHEMBL15710183 0.70 CYP1A2 (0.50) KDM4EL3MBTL1ALDH1A1MEN1MAPT
SCHEMBL4886275 0.69 POLB (0.43) KDM4EALDH1A1NTRK1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024134517-A1 NOVEL COMPOUND AS RON INHIBITOR 주식회사 엘지화학 2024-06-27 WO disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 KDM4E 2869/4885L3MBTL1 4714/4885OXTR 2563/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 KDM4E 2869/4885L3MBTL1 4714/4885OXTR 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.